Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t
Ocular Therapeutix: Data Confirms That The Future Is Bright
12:31pm, Monday, 25'th Jan 2021
Dextenza sales continue to grow despite the fact that COVID-19 cases are still continuing to rise. Recently, OCUL signed a deal to commercialize Dextenza and OTX-TIC internationally, proving the value
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
12:02pm, Wednesday, 06'th Jan 2021
Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.
Ocular TherapeutixTM Announces Exercise of Underwriters' Option to Purchase Additional Shares
08:00am, Monday, 28'th Dec 2020
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t
Ocular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up
03:03pm, Wednesday, 23'rd Dec 2020
The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021.
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock
09:47pm, Tuesday, 15'th Dec 2020
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
04:13pm, Monday, 14'th Dec 2020
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Revised)
02:13am, Friday, 06'th Nov 2020
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 26.09% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2020 Results - Earnings Call Transcript
09:36pm, Thursday, 05'th Nov 2020
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2020 Results - Earnings Call Transcript
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal
02:28pm, Sunday, 01'st Nov 2020
CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint rec
Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia
08:00am, Friday, 30'th Oct 2020
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
